LONG-TERM USE OF GLUCOCORTICOID MODULATED PARATHYROID HORMONE LEVELS IN OSTEOPOROSIS PATIENTS.

Glucocorticoids are drugs that are often used in both inpatient and outpatient settings. Their anti-inflammatory action is often utilized to treat a variety of diseases. A range of undesirable outcomes might occur with long-term glucocorticoid use, particularly long-term high-dose applications. This study designs as a case-control study, which was conducted in the Joint Enology Clinic/Al-Hilla Teaching Hospital, Al-Imam Al-Sadiq Hospital, and Merjan Teaching Hospital in Hilla City, Babylon Governorate of Iraq. This study was carried out between December 2022 to March 2023. In this study, the total number of subjects was 100; the patient group consisted of 50 with osteoporosis (19 males and 31 females). Patients and control group's ages were (41-50 years). They were selected as matched in terms of gender and age. The results referred to the increased levels, of parathyroid hormone in osteoporosis patients with highly significant differences (P≤0.0001) when compared with the control group, while there was a significant decrease in calcium in the patient group (P≤0.0001) when compared with the control group. In conclusion, the parathyroid hormone has a beneficial association to indicate bone mineralization status. Parathyroid hormone could be used as a prognostic marker in individuals with long-term use of glucocorticoid to predict the development of bone mineral disease.